SH-1028

Networked: 5 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 3-Ring Heterocyclic Compounds
    - SH-1028: 5
Organic Chemicals: 133
- Hydrocarbons: 1713
  - Acyclic Hydrocarbons
    - Alkanes: 241
      - Alkanesulfonic Acids
        Alkanesulfonates: 9
        Mesylates: 334
        SH-1028: 5
- Sulfur Compounds: 278
  - Sulfur Acids
    - Sulfonic Acids: 1605
      - Alkanesulfonic Acids
        Alkanesulfonates: 9
        Mesylates: 334
        SH-1028: 5

Experts

1.	Zhang, Xiaomeng: 2 articles (10/2022 - 01/2021)
2.	Chen, Jianhua: 1 article (10/2022)
3.	Chen, Xueqin: 1 article (10/2022)
4.	Du, Yingying: 1 article (10/2022)
5.	Han, Dong: 1 article (10/2022)
6.	Hu, Yanping: 1 article (10/2022)
7.	Li, Jin: 1 article (10/2022)
8.	Li, Mingjun: 1 article (10/2022)
9.	Li, Na: 1 article (10/2022)
10.	Li, Runpu: 1 article (10/2022)

Related Diseases

1.	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/01/2023 - "Safety, efficacy, and pharmacokinetics of SH-1028 in EGFR T790M-positive advanced non-small cell lung cancer patients: A dose-escalation phase 1 study." 01/01/2021 - "SH-1028, An Irreversible Third-Generation EGFR TKI, Overcomes T790M-Mediated Resistance in Non-Small Cell Lung Cancer." 06/01/2023 - "SH-1028 is an irreversible third-generation EGFR tyrosine kinase inhibitor (EGFR-TKI) for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC). " 02/01/2023 - "SH-1028 is a novel, potent, and highly selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) developed for the treatment of T790M Mutation-positive non-small cell lung cancer (NSCLC). "
2.	Neoplasms (Cancer) 01/01/2021 - "In this study, we explored the anti-tumor effect of SH-1028 in vitro and in vivo, the inhibition of cell signal, such as EGFR and ERK phosphorylation, and verified the relationship between the pharmacokinetics and pharmacodynamic responses. " 01/01/2021 - "Then, in mouse xenograft models, oral administration of SH-1028 at a daily dose of 5 mg/kg significantly inhibited proliferation of tumor cells with EGFR sensitive mutation (exon 19 del) and resistant mutation (T790 M) for consecutive 14 days, with no TKI-induced weight loss. "
3.	Disease Progression 01/01/2023 - "Patients received SH-1028 at five oral dose levels (60 mg, 100 mg, 200 mg, 300 mg, and 400 mg) once daily until disease progression, unacceptable toxicity, or patient withdrawal. " 10/01/2022 - "Each patient received SH-1028 tablets orally at 200 mg/d until disease progression or intolerable toxicity. "
4.	Weight Loss (Weight Reduction) 01/01/2021 - "Then, in mouse xenograft models, oral administration of SH-1028 at a daily dose of 5 mg/kg significantly inhibited proliferation of tumor cells with EGFR sensitive mutation (exon 19 del) and resistant mutation (T790 M) for consecutive 14 days, with no TKI-induced weight loss. "

Related Drugs and Biologics

1.	Tyrosine Kinase Inhibitors
2.	ErbB Receptors (EGF Receptor)
3.	Tablets

Related Therapies and Procedures

1.	Oral Administration